WallStSmart

Applovin Corp (APP)vsHaoxi Health Technology Limited (HAO)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Applovin Corp generates 12355% more annual revenue ($6.83B vs $54.83M). APP leads profitability with a 64.6% profit margin vs -17.4%. APP earns a higher WallStSmart Score of 79/100 (B+).

APP

Strong Buy

79

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 6.7Quality: 8.0
Piotroski: 6/9Altman Z: 3.74

HAO

Hold

49

out of 100

Grade: D+

Growth: 8.7Profit: 2.0Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 5.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APPSignificantly Overvalued (-46.4%)

Margin of Safety

-46.4%

Fair Value

$267.19

Current Price

$393.68

$126.49 premium

UndervaluedFair: $267.19Overvalued

Intrinsic value data unavailable for HAO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APP6 strengths · Avg: 10.0/10
PEG RatioValuation
0.5010/10

Growing faster than its price suggests

Return on EquityProfitability
152.0%10/10

Every $100 of equity generates 152 in profit

Profit MarginProfitability
64.6%10/10

Keeps 65 of every $100 in revenue as profit

Operating MarginProfitability
77.7%10/10

Strong operational efficiency at 77.7%

Revenue GrowthGrowth
52.8%10/10

Revenue surging 52.8% year-over-year

EPS GrowthGrowth
57.0%10/10

Earnings expanding 57.0% YoY

HAO5 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
137.3%10/10

Revenue surging 137.3% year-over-year

EPS GrowthGrowth
172.7%10/10

Earnings expanding 172.7% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.8010/10

Safe zone — low bankruptcy risk

Areas to Watch

APP2 concerns · Avg: 2.5/10
Debt/EquityHealth
1.073/10

Elevated debt levels

Price/BookValuation
41.7x2/10

Trading at 41.7x book value

HAO4 concerns · Avg: 2.0/10
Market CapQuality
$695,6403/10

Smaller company, higher risk/reward

Return on EquityProfitability
-15.5%2/10

ROE of -15.5% — below average capital efficiency

Free Cash FlowQuality
$-301,8302/10

Negative free cash flow — burning cash

Profit MarginProfitability
-17.4%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : APP

The strongest argument for APP centers on PEG Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 64.6% and operating margin at 77.7%. Revenue growth of 52.8% demonstrates continued momentum.

Bull Case : HAO

The strongest argument for HAO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 137.3% demonstrates continued momentum.

Bear Case : APP

The primary concerns for APP are Debt/Equity, Price/Book.

Bear Case : HAO

The primary concerns for HAO are Market Cap, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

APP profiles as a growth stock while HAO is a hypergrowth play — different risk/reward profiles.

APP carries more volatility with a beta of 2.56 — expect wider price swings.

HAO is growing revenue faster at 137.3% — sustainability is the question.

APP generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

APP scores higher overall (79/100 vs 49/100), backed by strong 64.6% margins and 52.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Applovin Corp

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

AppLovin Corporation is committed to creating a software-based platform for mobile application developers to improve the marketing and monetization of their applications globally. The company is headquartered in Palo Alto, California.

Visit Website →

Haoxi Health Technology Limited

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

Haoxi Health Technology Limited Class A Ordinary Shares is a pioneering force in the health technology sector, focused on revolutionizing healthcare through innovative, technology-driven solutions. The company harnesses advanced artificial intelligence and data analytics to enhance diagnostic precision, streamline treatment processes, and improve patient management. With a robust commitment to research and development, Haoxi is well-positioned to tackle emerging healthcare challenges, presenting substantial growth opportunities for institutional investors aiming to leverage advancements in this dynamic and rapidly evolving market.

Want to dig deeper into these stocks?